← Back to patent-cliff list
CAS 1497256-75-3
4-((4-(4-chloro-2-((2-fluoro-6-methoxyphenyl)(hydroxy)methyl)phenyl)-5-cyanopyrimidin-2-yl)amino)-2-methoxybenzoic acid
Codes: ALISE-017
Application context (from source-drug indications)
Breast cancerAlisertibMetastatic breast cancerAlisertibSmall cell lung cancerAlisertibSolid tumourAlisertibHead and neck squamous cell carcinomaAlisertib横纹肌样瘤Alisertib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Alisertib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-guanidino-2-methoxybenzoic acid hydrochloride→5-chloro-3-(2-fluoro-6-methoxyphenyl)isobenzofuran-1(3H)-one→2-(5-chloro-3-(2-fluoro-6-methoxyphenyl)-1-hydroxy-1,3-dihydroisobenzofuran-1-yl)acetonitrile→(E)-2-(5-chloro-3-(2-fluoro-6-methoxyphenyl)-1-hydroxy-1,3-dihydroisobenzofuran-1-yl)-3-(dimethylamino)acrylonitrile→4-((4-(4-chloro-2-((2-fluoro-6-methoxyphenyl)(hydroxy)methyl)phenyl)-5-cyanopyrimidin-2-yl)amino)-2-methoxybenzoic acid→4-((5-(aminomethyl)-4-(4-chloro-2-((2-fluoro-6-methoxyphenyl)(hydroxy)methyl)phenyl)pyrimidin-2-yl)amino)-2-methoxybenzoic acid
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.